Joining us today on the Daily Dive is that of DiagnaMed Holdings (CSE: DMED) Chairman Fabio Chianelli, and Dr. John Kounios, Principal Investigator of BrainAGE. Fabio and John sit down with us this afternoon to discuss artificial intelligence and its role in health care — and specifically in the case of DiagnaMed, brain health. We discuss the revenue model utilized by the company, a recent agreement with the University of Miami, and the timeline for the commercial rollout of CERVAI.
DiagnaMed is developing a platform of software-based digital diagnostics with the potential to improve the early detection of mental health and neurological disorders, overall patient health, and lower healthcare costs.
FULL DISCLOSURE: DiagnaMed Holdings is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover DiagnaMed Holdings on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
As the founder of The Deep Dive, Jay is focused on all aspects of the firm. This includes operations, as well as acting as the primary writer for The Deep Dive’s stock analysis. In addition to The Deep Dive, Jay performs freelance writing for a number of firms and has been published on Stockhouse.com and CannaInvestor Magazine among others.